Facts & Figures

Equity Story

Since our foundation in 1993, we have offered investors direct access to a select portfolio of promising, fast growing and profitable biotech companies listed on stock markets around the world. Thanks to our strong track record over the years and our systematic strategy and clear focus, we have become one of the world’s largest biotech investors and a European market leader.

Biotechnology is one of the most attractive of any sector today with estimated annual growth in the double-digits. Mega trends such as increasing life expectancy and a Westernized diet and lifestyle are powerful growth drivers. These mega trends have led to a tremendous increase in healthcare costs, which, in turn, only amplifies the need for more efficient and effective drugs.

Furthermore, many pharmaceutical giants are confronted with deep cuts in revenue streams as a result of patent expirations. They are now purchasing innovative biotech products in an attempt to replenish product pipelines and have been willing to pay top dollar in these deals.

Meanwhile every second drug approved today stems from the labs of a biotech company and many biotech firms have been reporting strong sales and profit growth. The biotech industry has obviously come of age and reached a certain level of maturity.

PERFORMANCE

27.07.2016
SIX Swiss ExchangeValueYTDsince Nov. 1993*
ShareCHF 49.25-10.3%1508.6%
Net Asset Value (NAV)CHF 53.90-19.6%1549.0%
Deutsche BörseValueYTDsince Dec. 1997*
ShareEUR 45.30-10.7%1182.0%
Net Asset Value (NAV)EUR 49.40-19.9%1212.9%
Borsa ItalianaValueYTDsince Oct. 2000*
ShareEUR 45.08-11.5%195.1%
Net Asset Value (NAV)EUR 49.40-19.9%203.1%


*Launch date

Facts & Figures

Foundation

November 9, 1993,
Schaffhausen, Switzerland

Issue price adj.
November 15,1993

CHF 23.76

Official Listing  

Switzerland: December 27, 1993
Germany: December 10,1997
Italy, October 19, 2000

Share structure

CHF 59.25 mn nominal, 59'250'000 registered shares with a par value of CHF 0.2

Shareholders, free float

Institutional and private investors

94.0% free float (6.0% treasury shares held on second trading line)

Security number Switzerland

3 838 999

Security number Germany and Italy

A0NFN3

ISIN

CH0038389992

Ticker Bloomberg

Switzerland: BION SW
Germany: BBZA GY
Italy: BB IM

Ticker Reuters

Switzerland: BION.S
Germany: BION.DE
Italy: BIO.MI

Type / asset classInvestment trust / equity
Investment approachLong only, long term
Index membershipStoxx Europe 600, Star Index
BenchmarkNasdaq Biotech Index (NBI)
Management FeeAll-in-Fee: 1.1% p.a.

 

 

Multi-year comparison

20152014201320122011

Market capitalization at the end of the period ( in mn CHF)

3463.22799.01668.51150.51017.0

Net Asset Value at the end of the period  (in CHF mn)

3978.23492.52118.91234.01001.7

Number of shares (in mn)

11.911.911.913.016.4

Trading volume (in mn CHF)

6265.23186.61289.3948.9775.9

Profit / loss  (in CHF mn)

652.81470.1931.8367.8-65.1

Closing price at the end of the period in CHF

292.25236.20140.8088.5062.00

Closing price (G) at the end of the period in EUR

269.95198.00115.2072.5550.98

Closing price (I) at the of the period in EUR

270.9196.70115.4072.9051.00

Stock performance (incl. distribution)

28.2%75.1%66.0%42.7%5.6%

High/low share price in CHF

351.25/232.4244.80/133.7146.90/89.5096.80/62.0067.40/43.15

High/low share price in EUR

330.1/196.95199.90/109.10119.70/73.4580.24/50.5555.00/39.30

Premium (discount) (annual average)

-17.6%-22.1%-23.1%-21.3%-19.6%

Dividen/cash distribution in CHF 

14.5011.607.004.500.00

Degree of investment (quarterly figures)

101.0%104.6%104.5%109.0%112.3%

Total Expense Ratio (TER) p.a.

1.13%1.14%1.02%1.69%1.02%

 

 

Analyst coverage

InstituteAnalyst
Deutsche BankGunnar Romer
EquinetMarietta Miemietz
Oddo SeydlerIgor Kim, Ivo Visic
EquitaMartino De Ambroggi
EdisonSarah Godfrey, Andrew Mitchell
Cantor FitzgeraldCharles Tan